B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GALR3

MOLECULAR TARGET

galanin receptor 3

UniProt: O60755NCBI Gene: 848412 compounds

GALR3 (galanin receptor 3) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GALR3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1dihydrorotenone1.614
2Etilefrine1.393
3Betamethasone1.102
4Cladribine1.102
5Salmeterol Xinafoate1.102
6tyrphostin 91.102
7Adenosine0.691
8Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide.0.691
9Digoxin0.691
10Lanatosides Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale,0.691
114-Hydroxybenzoate-3-Monooxygenase0.691
12Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide.0.691

About GALR3 as a Drug Target

GALR3 (galanin receptor 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented GALR3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GALR3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.